British Columbia (Canada) Denies Funding for MDS Drug Covered in Every Other Province

British Columbia (Canada) is facing criticism for refusing to fund Luspatercept, a medication used to treat MDS that is publicly covered in every other Canadian province. Luspatercept is a medication that helps the body produce more mature red blood cells, reducing or eliminating the need for blood transfusions and improving quality of life for many patients.

A recently published article on Canadian Global News describes the story of two women with MDS: Gwen Barry, an 84-year-old in Nova Scotia whose health and independence have dramatically improved thanks to Luspatercept, and Joey Kerr, an 80-year-old British Columbia resident who has been denied coverage and must continue monthly transfusions. Patient advocates and clinicians argue that the drug reduces long-term healthcare costs by lowering transfusion needs and preventing complications such as iron overload.

Gwen Barry explains the following about Luspatercept: “When it increases your red blood cells, you have more oxygen and it’s easier to live. You can walk longer, you can walk further. I swim 24 laps in the pool once a week and that’s pretty good for 84 years old. It’s kind of given me my life back.”

Cindy Anthony, executive director for the Aplastic Anemia & Myelodysplasia Association of Canada (AAMAC) and a member of the MDS Alliance Steering Committee, said they have been advocating for Luspatercept to be covered across Canada: “Why has every other province’s medical experts looked at this medication and said it’s a life-changer for these patients – and one province is not?”

British Columbia’s Health Minister says the province’s decisions are based on evidence reviews and cost-effectiveness assessments, but patient groups are urging the government to reconsider, noting that British Columbia is the only province not providing access to this treatment.

To read more about the story, please follow the link: Global News